Eledon Pharmaceuticals, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Eledon completed a successful FDA End-of-Phase 2 meeting for tegoprubart in kidney transplantation and plans to initiate a global Phase 3 trial in late 2026 enrolling ~600 patients, with primary endpoint of non-inferiority versus tacrolimus at 52 weeks. Cash, cash equivalents, and short-term investments totaled $88.8M as of June 30, 2026 (down from $133.3M at December 31, 2025), with the company expecting current resources to fund operations into Q2 2027. Q2 2026 net loss was $31.6M ($0.27 per share) versus $11.2M ($0.13 per share) in Q2 2025, with the increase driven by a $9.6M non-cash loss on warrant liability fair value changes.
Why this rating
FDA regulatory alignment on Phase 3 is a material clinical milestone for a ~$145M company; however, cash burn ($44.5M in H1 2026) and reliance on near-term funding limit significance. Execution risk remains high.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.